Loading...
Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer.
Grunnet, M Christensen, I Lassen, U Jensen, L Lydolph, M Knox, J Jitlal, M Wasan, H Bridgewater, J
Grunnet, M
Christensen, I
Lassen, U
Jensen, L
Lydolph, M
Knox, J
Jitlal, M
Wasan, H
Bridgewater, J
Citations
Altmetric:
Abstract
Carbohydrate associated antigen (CA19-9) has been approved by the FDA as a biomarker for monitoring treatment effect in pancreatic cancer. However, the value of serum CA19-9 as a biomarker of response to chemotherapy in bile duct cancer is unclear. The aim of this study was to determine if a decline in CA19-9 (CA19-9 response) during chemotherapy is predictive of survival in patients with inoperable bile duct cancer.
Description
Date
2015-07
Publisher
Collections
Keywords
Type
Article
Citation
Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer. 2015, 51 (11):1381-8 Eur J Cancer